Dr. Deol on the Nuances of Utilizing CAR T-Cell Therapy in Lymphoma and Leukemia

Video

Abhinav Deol, MD, discusses the nuances of utilizing CAR T-cell therapy in lymphoma and leukemia.

Abhinav Deol, MD, associate clinical professor, Barbara Ann Karmanos Cancer Institute, discusses the nuances of utilizing CAR T-cell therapy in lymphoma and leukemia.

CAR T-cell therapy is an important modality of treatment ​for patients with lymphoma and leukemia. 

​However, patients must demonstrate good performance status​, along with ​good social support ​to be eligible for treatment, says Deol. As such, CAR T-cell therapy may not be an option for every patient. 

Additionally, after ​patients receive an infusion ​of CAR T-cell therapy, they must be observed for potential neurological toxicity​, hypogammaglobulinemia​, and other long-term adverse effects that could require chronic immunoglobulin replacement​, Deol says. Moreover, patients may develop cytopenias that can last ​for up to 1 year ​following infusion. 

The field of lymphoma and leukemia continues to gain experience in administering this therapeutic modality and, in the near future, additional ​regulatory approvals for the modality are expected, Deol concludes. 

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.